Pharma boards are finally treating patent litigation like what it is: a balance-sheet risk with governance consequencesnot just a legal event.
Heres the uncomfortable truth: many executives still describe IP disputes in the language of strategy (defend…

Generic drug developers dont lose to bad luck. They lose to unforced errorsespecially around formulation patents.
If youre building a generic, you already know the obvious battlegrounds: active ingredient, dosage form, and route of administration. Bu…

Pharma forensics is having a momentand its not because everyone suddenly loves patent law.
Its because the industry is running out of time.
In a world where formulation patents can quietly extend market exclusivity, where minor changes can reset regula…

Designing Around the Moat: How Generic Developers Can Win the Secondary Patent Game
In pharma, the real fight rarely ends when the primary patent expires.
It starts there.
For generic developers, the moat is often not one wallits a layered fortress of …

Patent cliffs arent just a legal eventtheyre a supply chain stress test.
If youre responsible for procurement, planning, manufacturing, or commercial operations, the patent cliff conversation can feel abstract: a date on a calendar, a headline about ge…

Most prior art searches miss the point. Heres why AI/NLP is changing the game.
If youve ever run a patent search, you know the uncomfortable truth: the best prior art is often hiding in plain sightjust not under the keywords youre looking for.
Traditio…

Pharmas next IP chess move isnt invent around its design around.
If youre building a product pipeline in 2026 and beyond, youre not just racing for clinical differentiation. Youre racing for patent survivability. And one of the most misunderstood ba…

Most people read drug patents like theyre reading product specs. Thats the mistake.
If you want to understand where a generic challenge is headedor where a brands next life-cycle move is likely to landyou dont start with the active ingredient. You star…

The biosimilar patent dance isnt a formalityits a strategy war.
If youre a biologics sponsor or a biosimilar applicant, the rules may look procedural. But the outcomes are anything but. The patent dancebuilt around timing, notice, and litigation trig…

Generic manufacturers dont wait for exclusivitythey engineer it.
In the Paragraph IV world, the 180-day window isnt a prize you win by filing a lawsuit. Its a strategic asset you buildthrough timing, litigation posture, manufacturing readiness, and a…